)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
EyePoint Pharmaceuticals (EYPT) investor relations material
EyePoint Pharmaceuticals Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Cantor Global Healthcare Conference 2025 summary3 Sep, 2025
Clinical development progress
DuraVu, leveraging DuraCert technology, advanced from Phase I to two global Phase III trials in four years, each enrolling over 400 patients in record time.
Both Phase III trials, Lugano and Lucia, are identically designed with no protocol changes since inception, focusing on non-inferiority to aflibercept.
Lucia includes about 20% ex-U.S. patients, with overall 90% U.S. representation across both trials, aligning with FDA preferences.
Redosing is every six months for two years, aiming for an unlimited label; NDA submission will use 12-month data, supplemented by 24-month results.
Phase III data readouts are expected in Q3 2025, with Lugano first, followed by Lucia, enabling a rapid NDA filing.
Regulatory and commercial strategy
Both U.S. FDA and EU regulators have approved the clinical trial protocols, supporting global regulatory alignment.
U.S. launch is prioritized, with plans to commercialize independently; ex-U.S. partnerships will be considered later.
Commercial positioning emphasizes DuraVu’s unique TKI mechanism, offering a new MOA in wet AMD, and potential for use alongside anti-VEGF therapies.
Market strategy targets reduction in treatment burden and addresses unmet needs in a $14–15B wet AMD market.
DuraVu aims to be the first new MOA in wet AMD in 15 years, with potential for broad adoption due to its durability and differentiated profile.
Manufacturing and operational readiness
A new 41,000 sq. ft. commercial manufacturing facility in Massachusetts is operational, supporting U.S. and future global supply.
Registration batches are underway, with preparations for pre-approval inspection and commercial launch.
Both the product and key API are U.S.-manufactured, minimizing tariff exposure and ensuring supply chain control.
DuraVu's unique commercial positioning strategy
How does US manufacturing de-risk DuraVu launch?
What makes the DME opportunity compelling?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next EyePoint Pharmaceuticals earnings date
Q3 20256 Nov, 2025
Next EyePoint Pharmaceuticals earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic therapies. The company specializes in sustained-release drug delivery technologies to address serious eye diseases, including conditions affecting the retina and anterior segment of the eye. EyePoint’s product portfolio includes treatments for inflammation and other ocular disorders, and it supports both commercialized products and clinical development programs. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage